FILE - This Nov. 15, 2005 file photo shows 40 milligram tablets of Lipitor, one kind of statin used for lowering blood cholesterol, in Glen Rock, N.J. A study led by a Boston researcher and presented Monday, Nov. 14, 2011 finds that offering people free medicines after a heart attack can help cut the chances they will suffer another one. It also saves them about 500 for health care over the next year without raising costs for insurers. However, doctors were shocked that only about half of these patients filled their prescriptions even though they got them free. (AP Photo/Mel Evans, File)
FILE - This Nov. 15, 2005 file photo shows 40 milligram tablets of Lipitor, one kind of statin used for lowering blood cholesterol, in Glen Rock, N.J. A study led by a Boston researcher and presented Monday, Nov. 14, 2011 finds that offering people free medicines after a heart attack can help cut the chances they will suffer another one. It also saves them about 500 for health care over the next year without raising costs for insurers. However, doctors were shocked that only about half of these patients filled their prescriptions even though they got them free. (AP Photo/Mel Evans, File) Credit: Mel Evans

They may take to the halls of Congress and sing of the glories of the free market, but the last thing most companies, especially pharmaceutical companies, want is competition.

Millions spent on lobbying often allows them to avoid it, but with Democrats ascendant in the House and the Senate and the White House up for grabs in 2020, drug prices are finally getting the attention they deserve.

New Hampshire’s congressional delegation should be in the front ranks of the fight for fair, affordable, transparent drug prices. America’s consumers are being ripped off and people falling ill or worse because they can’t afford the drugs they need.

In 2017, in a suit joined by 46 states, including New Hampshire, Connecticut charged several of the nation’s major manufacturers of generic drugs with conspiring to fix prices at the expense of American consumers. One anti-trust investigator described the effort as probably the largest cartel in U.S. history.

“Prices for dozens of generic drugs have uncharacteristically risen – some have skyrocketed for no apparent reason . . . costs have doubled, tripled or in some cases, increased up to 1,000 percent or more. . . . . The reason underlying many of these price increases is more straightforward and sinister – collusion among generic drug competitors,” the suit contends. The investigation now includes more than 300 drugs and 16 companies.

Collusion by drug makers, if proven to exist, isn’t the only reason Americans pay far more for medications than residents of other nations. Mark-ups by pharmacies benefit companies, and group purchasing organizations play a role. So does U.S. patent law, which protects new drugs from competition from eight to 15 years or more. The absurd ban on allowing Medicare to use its purchasing power to negotiate discounted drug prices costs taxpayers and patients billions per year.

These cost drivers and more are under attack in Congress. Legislation includes a bipartisan bill sponsored by Iowa Republican Sen. Chuck Grassley and Illinois Democrat Richard Durbin that would require pharmaceutical companies to disclose the list prices of the medications they advertise incessantly.

The most provocative ideas, not surprisingly, come from activist Democratic Sens. Elizabeth Warren and Bernie Sanders. The latter has sponsored legislation that would allow the government, when the price of a drug is deemed excessive when compared to its price internationally, to license private companies to produce a generic version of the drug. Warren’s bill would do likewise, plus create a federal Office of Drug Manufacturing, which would be empowered to produce generic versions of any drug that it deems excessively priced or in critically short supply.

High prices result when a company has a monopoly over the supply of a drug, whether granted by patent protection or when only one maker or two makers of a generic drug exist. A Harvard Medical School study found that when two forms of a generic drug are on the market, the price falls by nearly half. When there are 10 makers, the price drops by three-quarters.

A Senate controlled by Republicans is extremely unlikely to pass either Warren or Sanders’s bill, but the public is fed up with the pharmaceutical industry, with chronic anxiety over health care affordability, and with Congress, so some progress could occur.

How much depends on how loudly and how often the public demands it.